 |
|
Dealing With Unanticipated Mortality in a Large Randomized Clinical Trial of Topical Tretinoin
Lisa M. Schilling, MD, MSPH;
Robert P. Dellavalle, MD, PhD, MSPH
Arch Dermatol. 2009;145(1):76.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
. . . I would urge you to cultivate a keenly skeptical attitude toward the pharmacopeia as a whole. . . . —Sir William Osler, 19071
Millions of people have used topical tretinoin to treat acne and photoaging.2-4 In this issue, Weinstock et al5 report an unexpected result that led to the premature halt of their randomized, placebo-controlled Department of Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) trial designed to determine whether topical tretinoin, 0.1%, cream prevents basal and squamous cell skin cancer in US veterans. Limited topical tretinoin use (up to twice daily to the face and ears) was associated with increased death (end-of-intervention hazard ratio, 1.54; P = .01).
While some argue that topical tretinoin might increase pulmonary-related mortality,6 Weinstock et al5 ultimately reject this explanation and chalk their results up as a chance finding based on the following: (1) minimal systemic absorption of . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Tretinoin: An Established Long-term Safety Profile--Reply
Katz
Arch Dermatol 2009;145:1064-1065.
FULL TEXT
Long-Term Topical Tretinoin and Excess Mortality in Older Patients
Journal Watch Dermatology 2009;2009:1-1.
FULL TEXT
|
